Oprah Winfrey didn't let a little thing like rain get in the way of her workout Friday. The media icon, 71, showcased her fit ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

BRINP2-related peptide, or BRP, is a naturally occurring molecule that can suppress appetite and promote weight loss in mice ...

With GLP-1 weight loss comes muscle loss. Gyms and personal trainers are rising to the challenge to help people build it back ...

Cena Hermus, 7, was two years old when she was diagnosed with a rare, life-threatening disorder that causes severe obesity.

Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...

Scientists have discovered a naturally-occurring molecule that rivals the weight-loss effects of semaglutide-based GLP-1s like Ozempic in animals.

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.